Company news
Frontier Biotechnologies Inc. news in 2024
Frontier Biotechnologies Inc.'s news releases, calls and decks from 2024, newest first.
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2024
December 27, 2024
Announcement on Resolution of the 18th Meeting of the 3rd Board of Supervisors
December 9, 2024
Announcement on the Renewal of Company Product Albuvirtide for Injection for Inclusion in the Catalogue of Drugs for Basic National Medical Insurance
November 28, 2024
Announcement on Progress in Selling Partial Equity of Wholly-owned Subsidiary and Renewal of Business License by Subsidiary
November 26, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 15, 2024
Announcement on Voluntary Disclosure of Adding API Supplier for Albuvirtide for Injection and Subsidiary Sichuan Frontier Biopharmaceutical Co., Ltd. Passing Drug GMP Compliance Inspection
November 6, 2024
Announcement on Voluntary Disclosure on Obtaining Notice of Approval for Phase II Clinical Trials of Aikening's New Maintenance Treatment Indications
November 5, 2024
Report for Q3 2024
October 30, 2024
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2024
October 28, 2024
Announcement on Selling Partial Equity of Wholly-owned Subsidiaries and Passively Forming External Loans and Guarantees
October 10, 2024
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2024
September 20, 2024
Announcement on Using Temporarily Idle Raised Funds for Cash Management
September 13, 2024